Cargando…

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Agbarya, Abed, Sarel, Ina, Ziv-Baran, Tomer, Schwartz, Orna, Shechtman, Yelena, Kozlener, Ella, Khoury, Rasha, Sheikh-Ahmad, Mohammad, Saiegh, Leonard, Swaid, Forat, Ahmad, Asala Abu, Janzic, Urska, Brenner, Ronen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/
https://www.ncbi.nlm.nih.gov/pubmed/37873772
http://dx.doi.org/10.3390/diseases11040128
_version_ 1785124670334304256
author Agbarya, Abed
Sarel, Ina
Ziv-Baran, Tomer
Schwartz, Orna
Shechtman, Yelena
Kozlener, Ella
Khoury, Rasha
Sheikh-Ahmad, Mohammad
Saiegh, Leonard
Swaid, Forat
Ahmad, Asala Abu
Janzic, Urska
Brenner, Ronen
author_facet Agbarya, Abed
Sarel, Ina
Ziv-Baran, Tomer
Schwartz, Orna
Shechtman, Yelena
Kozlener, Ella
Khoury, Rasha
Sheikh-Ahmad, Mohammad
Saiegh, Leonard
Swaid, Forat
Ahmad, Asala Abu
Janzic, Urska
Brenner, Ronen
author_sort Agbarya, Abed
collection PubMed
description The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38–42.12), p = 0.02 and 17.15 (95% CI 5.01–58.7), p < 0.01, respectively). Unlike the response after two doses, the third and fourth BNT162b2 vaccine booster doses had an increased efficacy of 95–100% in cancer patients while undergoing active treatment. This result could be explained by different mechanisms including the development of memory B cells.
format Online
Article
Text
id pubmed-10594524
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105945242023-10-25 Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments Agbarya, Abed Sarel, Ina Ziv-Baran, Tomer Schwartz, Orna Shechtman, Yelena Kozlener, Ella Khoury, Rasha Sheikh-Ahmad, Mohammad Saiegh, Leonard Swaid, Forat Ahmad, Asala Abu Janzic, Urska Brenner, Ronen Diseases Article The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38–42.12), p = 0.02 and 17.15 (95% CI 5.01–58.7), p < 0.01, respectively). Unlike the response after two doses, the third and fourth BNT162b2 vaccine booster doses had an increased efficacy of 95–100% in cancer patients while undergoing active treatment. This result could be explained by different mechanisms including the development of memory B cells. MDPI 2023-09-26 /pmc/articles/PMC10594524/ /pubmed/37873772 http://dx.doi.org/10.3390/diseases11040128 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Agbarya, Abed
Sarel, Ina
Ziv-Baran, Tomer
Schwartz, Orna
Shechtman, Yelena
Kozlener, Ella
Khoury, Rasha
Sheikh-Ahmad, Mohammad
Saiegh, Leonard
Swaid, Forat
Ahmad, Asala Abu
Janzic, Urska
Brenner, Ronen
Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
title Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
title_full Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
title_fullStr Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
title_full_unstemmed Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
title_short Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
title_sort response rate of the third and fourth doses of the bnt162b2 vaccine administered to cancer patients undergoing active anti-neoplastic treatments
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/
https://www.ncbi.nlm.nih.gov/pubmed/37873772
http://dx.doi.org/10.3390/diseases11040128
work_keys_str_mv AT agbaryaabed responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT sarelina responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT zivbarantomer responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT schwartzorna responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT shechtmanyelena responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT kozlenerella responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT khouryrasha responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT sheikhahmadmohammad responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT saieghleonard responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT swaidforat responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT ahmadasalaabu responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT janzicurska responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments
AT brennerronen responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments